Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer

Fig. 2

TET2 was poly-ubiquitinated and degraded in EGFR-TKI resistant NSCLC cells. a Immunoblot analyses of TET2 in HCC827-OR cells treated with MG132 or CQ (chloroquine) for 8 h. b IB analyses of TET2 IP (immunoprecipitation) products and WCL (whole cell lysate) derived from HCC827 or HCC827-OR cells treated with or without MG132 for 12 h before collection. IB analyses of TET2 in parental HCC827 (c) or PC-9 (d) cells and their corresponding EGFR-TKI resistant derivatives treated with MG132 or CQ for 8 h. IB analyses of TET2 IP products and WCL derived from parental HCC827 (e) or PC-9 (f) cells and their corresponding EGFR-TKI resistant cells treated with MG132 for 12 h before collection. All data are representative of at least two independent experiments

Back to article page